Shares in Paratek were up almost a third in premarket trading this morning after Bloomberg said the company, gearing up to file a new antibiotic, is…

Encore Dermatology has picked up a late-stage pipeline drug via a deal with India's Dr. Reddy's Laboratories.

The multiyear agreement positions Lilly to work with Topas on drugs that convey tolerance to antigens linked to inflammation or autoimmune diseases.

The money will equip Krystal’s ex-Intrexon executive team to file an IND for its rare skin disease gene therapy in the first quarter of next year.

Axial Biotherapeutics has poached Srinivas G. Rao, M.D., Ph.D., from struggling DepoMed as its new chief medical officer.

Former Zealand Pharma chief David Horn Solomon, M.D., has taken up the challenge of guiding biotech Akari during an increasingly tumultuous period.

Samsung is taking its first steps beyond the lower risk, lower reward world of biosimilars by teaming up with Takeda to co-develop drugs.

Alkermes has started a rolling application to market its twice-failed antidepressant ALKS 5461.

The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.